Startseite Medizin Serum carbohydrate sulfotransferase 7 in lung cancer and non-malignant pulmonary inflammations
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Serum carbohydrate sulfotransferase 7 in lung cancer and non-malignant pulmonary inflammations

  • Željko Debeljak EMAIL logo , Sandra Dundović , Sonja Badovinac , Sanja Mandić , Miroslav Samaržija , Branko Dmitrović , Marija Miloš , Lana Maričić , Vatroslav Šerić und Vikica Buljanović
Veröffentlicht/Copyright: 12. April 2018
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 56 Heft 8

Abstract

Background:

Carbohydrate sulfotransferases (CHST) were shown to be involved in carcinogenesis. The aim of the study was to assess the diagnostic value of serum CHST7 concentration in differentiation between lung cancer and non-malignant pulmonary inflammations.

Methods:

Clinical case-control study involving 125 participants was conducted: the control group containing cases of pneumonia and chronic obstructive pulmonary disease was compared to the lung cancer group composed of primary and metastatic cancers. Serum concentrations of CHST7 and routinely used markers including carcinoembryonic antigen (CEA), cytokeratin fragment 21-1 (CYFRA 21-1) and neuron-specific enolase (NSE) were determined for each participant using immunochemical methods. Statistical association, receiver operating characteristic (ROC) analysis and cross-validation were used for the evaluation of CHST7 either as a standalone biomarker or as a part of a biomarker panel.

Results:

In comparison to the control group, serum CHST7 was elevated in lung cancer (p<0.001), but no differences between the overall stages of primary cancers were detected (p=0.828). The differentiation performance in terms of ROC area under curve (AUC) was 0.848 making CHST7 superior biomarker to the NSE (p=0.031). In comparison to CEA and CYFRA 21-1, the performance differences were not detected. CHST7 was not correlated to other biomarkers, and its addition to the routine biomarker panel significantly improved the cross-validated accuracy (85.6% vs. 75.2%) and ROC AUC (p=0.004) of the differentiation using a machine learning approach.

Conclusions:

Serum CHST7 is a promising biomarker for the differentiation between lung cancer and non-malignant pulmonary inflammations.

Keywords: biomarker; carbohydrate sulfotransferase; CHST7; lung cancer
Corresponding author: Assist. Prof. Željko Debeljak, PhD, Institute of Clinical Laboratory Diagnostics, Osijek University Hospital, Josipa Huttlera 4, 31 000Osijek, Croatia, Phone: +385 31 511 650

Acknowledgments

The authors would like to thank Dario Mandić and Mirjana Fijačko, Osijek University Hospital, Croatia; Mirjana Horvat, Našice General Hospital, Croatia; and Dunja Buljubašić, Blekingesjukhuset, Karlshamn, Sweden, for assistance in sample collection and in ELISA measurements. The authors would also like to thank Larisa Miller, Sanofi Genzyme, USA, for useful comments and suggestions.

  1. Author contributions: ŽD, SD, BD and SB conceived and designed the experiments. SD, ŽD, SM, SB and MM performed the experiments. ŽD, SD, SM, SB, LM and MS analyzed the data. ŽD, VŠ, VB and MS coordinated the research. VŠ and VB contributed reagents, materials and analysis tools. ŽD, SM, SB and SD wrote the manuscript. MM, MS, BD and LM revised the manuscript. ŽD supervised the research. All authors read and approved the final manuscript.

  2. Research funding: This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

  3. Employment or leadership: None declared.

  4. Honorarium: ZD has received honorariums from Shimadzu and ChromSystems. LM has received speaker honorariums from Berlin-Chemie, Servier Pharma, Boehringer Ingelheim, Bayer Pharmacy. SD, SB, SM, MS, BD, MM, VS and VB declare receiving no relevant honorariums.

  5. Competing interests: None declared.

References

1. Kitagawa H, Fujita M, Ito N, Sugahara K. Molecular cloning and expression of a novel chondroitin 6-O-sulfotransferase. J Biol Chem 2000;28:21075–80.10.1074/jbc.M002101200Suche in Google Scholar

2. Cooney CA, Jousheghany F, Yao-Borengasser A, Phanavanh B, Gomes T, Kieber-Emmons AM, et al. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res 2011;13:R58.10.1186/bcr2895Suche in Google Scholar

3. Cattaruzza S, Schiappacassi M, Kimata K, Colombatti A, Perris R. The globular domains of PG-M/versican modulate the proliferation-apoptosis equilibrium and invasive capabilities of tumor cells. FASEB J 2004;18:779–81.10.1096/fj.03-0660fjeSuche in Google Scholar

4. Pirinen R, Leinonen T, Böhm J, Johansson R, Ropponen K, Kumpulainen E, et al. Versican in non-small cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Hum Pathol 2005;36:44–50.10.1016/j.humpath.2004.10.010Suche in Google Scholar

5. Ly M, Laremore TN, Linhardt RJ. Proteoglycomics: recent progress and future challenges. OMICS 2010;14:389–99.10.1089/omi.2009.0123Suche in Google Scholar

6. Stylianou M, Skandalis SS, Papadas TA, Mastronikolis NS, Theocharis DA, Papageorgakopoulou N, et al. Stage-related decorin and versican expression in human laryngeal cancer. Anticancer Res 2008;28:245–51.Suche in Google Scholar

7. Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, et al. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 2004;10:2491–8.10.1158/1078-0432.CCR-03-0146Suche in Google Scholar

8. Tammi RH, Kultti A, Kosma VM, Pirinen R, Auvinen P, Tammi MI. Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol 2008;18:288–95.10.1016/j.semcancer.2008.03.005Suche in Google Scholar

9. Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB. The interaction of versican with its binding partners. Cell Res 2005;15:483–94.10.1038/sj.cr.7290318Suche in Google Scholar

10. Ruffell B, Poon GF, Lee SS, Brown KL, Tjew SL, Cooper J, et al. Differential use of chondroitin sulfate to regulate hyaluronan binding by receptor CD44 in inflammatory and interleukin 4-activated macrophages. J Biol Chem 2011;286:19179–90.10.1074/jbc.M110.200790Suche in Google Scholar

11. Pirinen R, Tammi R, Tammi M, Hirvikoski P, Parkkinen JJ, Johansson R, et al. Prognostic value of hyaluronan expression in non-small-cell lung cancer: increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int J Cancer 2001;95:12–7.10.1002/1097-0215(20010120)95:1<12::AID-IJC1002>3.0.CO;2-ESuche in Google Scholar

12. Vachon E, Martin R, Plumb J, Kwok V, Vandivier RW, Glogauer M, et al. CD44 is a phagocytic receptor. Blood 2006;107:4149–58.10.1182/blood-2005-09-3808Suche in Google Scholar PubMed

13. Luo Z, Wu RR, Lv L, Li P, Zhang LY, Hao OL, et al. Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review. Int J Clin Exp Pathol 2014;7:3632–46.Suche in Google Scholar

14. Ween PM, Oehler KM, Ricciardelli C. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci 2011;12:1009–29.10.3390/ijms12021009Suche in Google Scholar PubMed PubMed Central

15. Sanchez-Palencia A, Gomez-Morales M, Gomez-Capilla JA, Pedraza V, Boyero L, Rosell R, et al. Gene expression profiling reveals novel biomarkers in non-small cell lung cancer. Int J Cancer 2011;129:355–64.10.1002/ijc.25704Suche in Google Scholar PubMed

16. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One 2010;5:e10312.10.1371/journal.pone.0010312Suche in Google Scholar PubMed PubMed Central

17. Showe MK, Vachani A, Kossenkov AV, Yousef M, Nichols C, Nikonova EV, et al. Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res 2009;69:9202–10.10.1158/0008-5472.CAN-09-1378Suche in Google Scholar PubMed PubMed Central

18. Scott A, Salgia R. Biomarkers in lung cancer: from early detection to novel therapeutics and decision making. Biomark Med 2008;2:577–86.10.2217/17520363.2.6.577Suche in Google Scholar PubMed PubMed Central

19. Qi W, Li X, Kang J. Advances in the study of serum tumor markers of lung cancer. J Canc Res Ther 2014;10:95–101.10.4103/0973-1482.145801Suche in Google Scholar PubMed

20. Doseeva V, Colpitts T, Gao G, Woodcock J, Knezevic V. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer. J Transl Med 2015;13:55.10.1186/s12967-015-0419-ySuche in Google Scholar PubMed PubMed Central

21. Durham AL, Adcock IM. The relationship between COPD and lung cancer. Lung Cancer 2015;90:121–7.10.1016/j.lungcan.2015.08.017Suche in Google Scholar PubMed PubMed Central

22. Takiguchi Y, Sekine I, Iwasawa S, Kurimoto R, Tatsumi K. Chronic obstructive pulmonary disease as a risk factor for lung cancer. World J Clin Oncol 2014;5:660–6.10.5306/wjco.v5.i4.660Suche in Google Scholar PubMed PubMed Central

23. Gonzalez J, Marin M, Sanchez-Salcedo P, Zulueta JJ. Lung cancer screening in patients with chronic obstructive pulmonary disease. Ann Transl Med 2016;4:160.10.21037/atm.2016.03.57Suche in Google Scholar PubMed PubMed Central

24. Punturieri A, Szabo E, Croxton TL, Shapiro SD, Dubientt SM. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst 2009;101:554–9.10.1093/jnci/djp023Suche in Google Scholar PubMed PubMed Central

25. Sekine Y, Katsura H, Koh E, Hiroshima K, Fujisawa T. Early detection of COPD is important for lung cancer surveillance. Eur Respir J 2012;39:1230–40.10.1183/09031936.00126011Suche in Google Scholar PubMed

26. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumour MARKer prognostic studies (REMARK). Brit J Cancer 2005;9:387–91.10.1038/sj.bjc.6602678Suche in Google Scholar PubMed PubMed Central

27. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Clin Chem 2015;61: 1446–52.10.1373/clinchem.2015.246280Suche in Google Scholar PubMed

28. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2194.Suche in Google Scholar

29. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015;10:1243–60.10.1097/JTO.0000000000000630Suche in Google Scholar PubMed

30. Chheang S, Brown K. Lung cancer staging: clinical and radiologic perspectives. Semin Intervent Radiol 2013;30:99–113.10.1055/s-0033-1342950Suche in Google Scholar PubMed PubMed Central

31. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45.10.2307/2531595Suche in Google Scholar

32. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77.10.1186/1471-2105-12-77Suche in Google Scholar PubMed PubMed Central

33. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2011;21:3940–1.10.1093/bioinformatics/bti623Suche in Google Scholar PubMed

34. Breiman L. Random forests. Mach Learn 2001;45:5–32.10.1023/A:1010933404324Suche in Google Scholar

35. Liaw A, Wiener M. Classification and regression by random forest. R News 2002;2:18–22.Suche in Google Scholar

36. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2014.Suche in Google Scholar

37. Quatromoni JG, Eruslanov E. Tumor-associated macrophages: function, phenotype and link to prognosis in human lung cancer. Am J Transl Res 2012;4:376–89.Suche in Google Scholar

Received: 2017-12-12
Accepted: 2018-03-02
Published Online: 2018-04-12
Published in Print: 2018-07-26

©2018 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorials
  3. Procalcitonin for diagnosing and monitoring bacterial infections: for or against?
  4. Is it time to abandon the Nobel Prize?
  5. In Memoriam
  6. Norbert Tietz, 13th November 1926–23rd May 2018
  7. Reviews
  8. Procalcitonin guidance in patients with lower respiratory tract infections: a systematic review and meta-analysis
  9. Telomere biology and age-related diseases
  10. Opinion Paper
  11. Procalcitonin-guided antibiotic therapy: an expert consensus
  12. Genetics and Molecular Diagnostics
  13. mRNA expression profile in peripheral blood mononuclear cells based on ADRB1 Ser49Gly and Arg389Gly polymorphisms in essential hypertension — a case-control pilot investigation in South Indian population
  14. General Clinical Chemistry and Laboratory Medicine
  15. External quality assessment schemes for glucose measurements in Germany: factors for successful participation, analytical performance and medical impact
  16. Long-term stability of glucose: glycolysis inhibitor vs. gel barrier tubes
  17. Observational studies on macroprolactin in a routine clinical laboratory
  18. Anti-streptavidin IgG antibody interference in anti-cyclic citrullinated peptide (CCP) IgG antibody assays is a rare but important cause of false-positive anti-CCP results
  19. Point-of-care creatinine testing for kidney function measurement prior to contrast-enhanced diagnostic imaging: evaluation of the performance of three systems for clinical utility
  20. Hematology and Coagulation
  21. Analytical performance of an automated volumetric flow cytometer for quantitation of T, B and natural killer lymphocytes
  22. Lupus anticoagulant testing using two parallel methods detects additional cases and predicts persistent positivity
  23. Reference Values and Biological Variations
  24. Within-subject biological variation of activated partial thromboplastin time, prothrombin time, fibrinogen, factor VIII and von Willebrand factor in pregnant women
  25. Within-subject and between-subject biological variation estimates of 21 hematological parameters in 30 healthy subjects
  26. Immunoglobulin G (IgG) and IgG subclass reference intervals in children, using Optilite® reagents
  27. Cancer Diagnostics
  28. Serum carbohydrate sulfotransferase 7 in lung cancer and non-malignant pulmonary inflammations
  29. Cardiovascular Diseases
  30. Clinical performance of a new point-of-care cardiac troponin I test
  31. Diabetes
  32. Testing for HbA1c, in addition to the oral glucose tolerance test, in screening for abnormal glucose regulation helps to reveal patients with early β-cell function impairment
  33. Effects of common hemoglobin variants on HbA1c measurements in China: results for α- and β-globin variants measured by six methods
  34. Infectious Diseases
  35. Serum procalcitonin concentration within 2 days postoperatively accurately predicts outcome after liver resection
  36. Predictive value of serum gelsolin and Gc globulin in sepsis – a pilot study
  37. Cerebrospinal fluid free light chains as diagnostic biomarker in neuroborreliosis
  38. Letter to the Editor
  39. Glucose and total protein: unacceptable interference on Jaffe creatinine assays in patients
  40. Interference of glucose and total protein on Jaffe-based creatinine methods: mind the covolume
  41. Interference of glucose and total protein on Jaffe based creatinine methods: mind the covolume – reply
  42. Measuring procalcitonin to overcome heterophilic-antibody-induced spurious hypercalcitoninemia
  43. Paraprotein interference in the diagnosis of hepatitis C infection
  44. Timeo apis mellifera and dona ferens: bee sting-induced Kounis syndrome
  45. Bacterial contamination of reusable venipuncture tourniquets in tertiary-care hospital
  46. Detection of EDTA-induced pseudo-leukopenia using automated hematology analyzer with VCS technology
  47. Early adjustment of antimicrobial therapy after PCR/electrospray ionization mass spectrometry-based pathogen detection in critically ill patients with suspected sepsis
  48. Thromboelastometry reveals similar hemostatic properties of purified fibrinogen and a mixture of purified cryoprecipitate protein components
  49. Bicarbonate interference on cobas 6000 c501 chloride ion-selective electrodes
https://doi.org/10.1515/cclm-2017-1157
Schlagwörter für diesen Artikel
biomarker; carbohydrate sulfotransferase; CHST7; lung cancer

Artikel in diesem Heft

  1. Frontmatter
  2. Editorials
  3. Procalcitonin for diagnosing and monitoring bacterial infections: for or against?
  4. Is it time to abandon the Nobel Prize?
  5. In Memoriam
  6. Norbert Tietz, 13th November 1926–23rd May 2018
  7. Reviews
  8. Procalcitonin guidance in patients with lower respiratory tract infections: a systematic review and meta-analysis
  9. Telomere biology and age-related diseases
  10. Opinion Paper
  11. Procalcitonin-guided antibiotic therapy: an expert consensus
  12. Genetics and Molecular Diagnostics
  13. mRNA expression profile in peripheral blood mononuclear cells based on ADRB1 Ser49Gly and Arg389Gly polymorphisms in essential hypertension — a case-control pilot investigation in South Indian population
  14. General Clinical Chemistry and Laboratory Medicine
  15. External quality assessment schemes for glucose measurements in Germany: factors for successful participation, analytical performance and medical impact
  16. Long-term stability of glucose: glycolysis inhibitor vs. gel barrier tubes
  17. Observational studies on macroprolactin in a routine clinical laboratory
  18. Anti-streptavidin IgG antibody interference in anti-cyclic citrullinated peptide (CCP) IgG antibody assays is a rare but important cause of false-positive anti-CCP results
  19. Point-of-care creatinine testing for kidney function measurement prior to contrast-enhanced diagnostic imaging: evaluation of the performance of three systems for clinical utility
  20. Hematology and Coagulation
  21. Analytical performance of an automated volumetric flow cytometer for quantitation of T, B and natural killer lymphocytes
  22. Lupus anticoagulant testing using two parallel methods detects additional cases and predicts persistent positivity
  23. Reference Values and Biological Variations
  24. Within-subject biological variation of activated partial thromboplastin time, prothrombin time, fibrinogen, factor VIII and von Willebrand factor in pregnant women
  25. Within-subject and between-subject biological variation estimates of 21 hematological parameters in 30 healthy subjects
  26. Immunoglobulin G (IgG) and IgG subclass reference intervals in children, using Optilite® reagents
  27. Cancer Diagnostics
  28. Serum carbohydrate sulfotransferase 7 in lung cancer and non-malignant pulmonary inflammations
  29. Cardiovascular Diseases
  30. Clinical performance of a new point-of-care cardiac troponin I test
  31. Diabetes
  32. Testing for HbA1c, in addition to the oral glucose tolerance test, in screening for abnormal glucose regulation helps to reveal patients with early β-cell function impairment
  33. Effects of common hemoglobin variants on HbA1c measurements in China: results for α- and β-globin variants measured by six methods
  34. Infectious Diseases
  35. Serum procalcitonin concentration within 2 days postoperatively accurately predicts outcome after liver resection
  36. Predictive value of serum gelsolin and Gc globulin in sepsis – a pilot study
  37. Cerebrospinal fluid free light chains as diagnostic biomarker in neuroborreliosis
  38. Letter to the Editor
  39. Glucose and total protein: unacceptable interference on Jaffe creatinine assays in patients
  40. Interference of glucose and total protein on Jaffe-based creatinine methods: mind the covolume
  41. Interference of glucose and total protein on Jaffe based creatinine methods: mind the covolume – reply
  42. Measuring procalcitonin to overcome heterophilic-antibody-induced spurious hypercalcitoninemia
  43. Paraprotein interference in the diagnosis of hepatitis C infection
  44. Timeo apis mellifera and dona ferens: bee sting-induced Kounis syndrome
  45. Bacterial contamination of reusable venipuncture tourniquets in tertiary-care hospital
  46. Detection of EDTA-induced pseudo-leukopenia using automated hematology analyzer with VCS technology
  47. Early adjustment of antimicrobial therapy after PCR/electrospray ionization mass spectrometry-based pathogen detection in critically ill patients with suspected sepsis
  48. Thromboelastometry reveals similar hemostatic properties of purified fibrinogen and a mixture of purified cryoprecipitate protein components
  49. Bicarbonate interference on cobas 6000 c501 chloride ion-selective electrodes
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2026 De Gruyter Brill
Heruntergeladen am 24.1.2026 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2017-1157/html
Button zum nach oben scrollen